Sona Nanotech Receives ‘Deprioritization’ from FDA; Health Canada Evaluation Continues

You may also like

BioVaxys and Sona Nanotech Enter Research Collaboration

Sona Nanotech Announces Annual Options Grants

Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model

Sona Nanotech to Present Targeted Hyperthermia Therapy at the 19th International Canadian Melanoma Conference